| [1] |
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncol, 2012, 13(3): 239-246.
|
| [2] |
Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(2): 213-222.
|
| [3] |
Fei G. The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer[J]. J Cancer, 2017, 8(10)：1865-1871.
|
| [4] |
Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[J]. Cancer Discov, 2014, 4(9): 1046-1061.
|
| [5] |
杜亚茜，马煜辉，杨长绍，等．非小细胞肺癌患者外周血ctDNA样本中EGFR？T790M基因突变分析[J]. 实用医学杂志，2017，33(19)：3228-3232.
|
| [6] |
Soria JC, Mok TS, Cappuzzo F, et al. EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects[J]. Cancer Treat Rev, 2012, 38(5): 416-430.
|
| [7] |
Shi Y, Au JSK, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non–small-cell lung cancer of adenocarcinoma histology (PIONEER)[J]. J Thorac Oncol, 2014, 9(2): 154-162.
|
| [8] |
Yeh P, Chen H, Andrews J, et al. DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy[J]. Clin Cancer Res, 2013, 19(7): 1894-1901.
|
| [9] |
Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer[J]. Lancet Oncol, 2015, 16(9): e447-e459.
|
| [10] |
Jiang T, Zhou C. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor—resistant non-small cell lung cancer[J]. Transl Lung Cancer Res, 2014, 3(6): 370-372.
|
| [11] |
Jänne PA, Yang JC, Kim W, et al. AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer[J]. N Engl J Med, 2015, 372(18): 1689-1699.
|
| [12] |
Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer[J]. J Hematol Oncol, 2016, 9(1): 34.
|
| [13] |
Song HN, Jung KS, Yoo KH, et al. Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non–small cell lung cancer[J]. J Thorac Oncol, 2016, 11(4): e45-e47.
|
| [14] |
Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M[J]. Nat Med, 2015, 21(6): 560-562.
|
| [15] |
Niederst MJ, Hu H, Mulvey HE, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies[J]. Clin Cancer Res, 2015, 21(17): 3924-3933.
|
| [16] |
Noda S, Kanda S. Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer[J]. Expert Rev Respir Med, 2016, 10(5): 547-556.
|
| [17] |
Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M[J]. Nat Med, 2015, 21(6): 560-562.
|
| [18] |
Ercan D, Choi HG, Yun CH, et al. EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors[J]. Clin Cancer Res, 2015, 21(17): 3913-3923.
|
| [19] |
Helena AY, Tian K, Drilon AE, et al. Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain[J]. JAMA Oncol, 2015, 1(7): 982-984.
|
| [20] |
Piotrowska Z, Niederst MJ, Karlovich CA, et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor[J]. Cancer Discov, 2015, 5(7): 713-722.
|
| [21] |
Planchard D, Loriot Y, Andre F, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients[J]. Ann Oncol, 2015, 26(10): 2073-2078.
|
| [22] |
Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-na？ve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)[J]. Ann Oncol, 2012, 24(1): 54-59.
|
| [23] |
Mitsudomi T, Morita S, Yatabe Y, et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR)[J]．J Clin Oncol, 2012, 30: 485s (suppl; abstr 7521)．
|
| [24] |
Zhou C, Wu YL, Liu X, et al. Overall survival (OS) results from OPTIMAL (CTONG0802), a phase Ⅲ trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients withEGFR mutation-positive advanced non-small cell lung cancer (NSCLC)[J]. J Clin Oncol，2012; 30: 485s(suppl; abstr 7520)．
|
| [25] |
Jänne PA, Wang X, Socinski MA, et al. Randomized phase Ⅱ trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial[J]. J Clin Oncol，2012, 30(17): 2063-2069.
|
| [26] |
Sugawara S, Oizumi S, Minato K, et al. Randomized phase Ⅱ study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902[J]. Ann Oncol, 2015, 26(5): 888-894.
|
| [27] |
魏媛，马新宇，马笛，等. 一线EGFR-TKI耐药后接受化疗的晚期非小细胞肺癌患者疗效分析[J]. 实用医学杂志，2016, 32(2): 228-231.
|
| [28] |
Cheng H, An SJ, Zhang XC, et al. In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines[J]. Cancer Chemother Pharmacol, 2011, 67(3): 637-646.
|
| [29] |
Yamaguchi H, Hsu J L, Chen C T, et al. Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells[J]. Clin Cancer Res, 2013, 19(4): 845-854.
|
| [30] |
吴惠珍，邱学佳，段宝京，等. 贝伐珠单抗联合厄洛替尼治疗NSCLC疗效及安全性Meta分析[J]. 中华肿瘤防治杂志，2017, 24(9): 637-643.
|
| [31] |
Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study[J]. Lancet Oncol, 2014, 15(11): 1236-1244.
|
| [32] |
Furugaki K, Fukumura J, Iwai T, et al. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification[J]. Int J Cancer, 2016, 138(4): 1024-1032.
|
| [33] |
Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer[J]. J Clin Invest, 2009, 119(10): 3000-3010.
|
| [34] |
Janjigian YY, Smit EF, Groen HJ, et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor–resistant EGFR-mutant lung cancer with and without T790M mutations[J]. Cancer Discov, 2014, 4(9): 1036-1045.
|